(800) 429-3205

Are You a Hims & Hers Health Investor? Submit Your Information to Learn More About Our Investigation

Berger Montague is currently investigating a potential securities class action on behalf of shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).

Please view our terms of use policy and our privacy policy.

First Name *

Last Name *

Email *

Phone Number *

Address

City

Zip

State

Are you a current or former employee of Hims & Hers Health?

How many shares did you purchase? Please provide ALL transactions.

What dates did you purchase? Please provide ALL dates.

What was the price per share when you purchased? Please provide ALL prices.

Terms of Use *

I agree to the terms of service

Subscribe

I would like to receive updates from Berger Montague

Thank you! Your form has been successfully submitted.

About the Investigation

On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, alleging that the company engaged in deceptive marketing and sold unapproved compounded versions of semaglutide. Following the announcement, shares of Hims & Hers declined by over 26% in intraday trading, reflecting investor concerns regarding regulatory compliance and reputational risks.

Berger Montague’s investigation focuses on whether Hims & Hers and certain officers and directors made materially false or misleading statements or omitted material information regarding the nature and regulatory status of its GLP-1 offerings, the associated risks, and the partnership with Novo Nordisk.

If you are a Hims & Hers investor and would like to learn more about our investigation, please contact Berger Montague using the form above.